Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells.
about
Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cellsp22phox confers resistance to cisplatin, by blocking its entry into the nucleus.SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancerAPRIL, BCMA and TACI proteins are abnormally expressed in non-small cell lung cancer.Per2 participates in AKT-mediated drug resistance in A549/DDP lung adenocarcinoma cells.Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells.Strategic targeting of the PI3K-NFκB axis in cisplatin-resistant NSCLC.Cisplatin hepatotoxicity mediated by mitochondrial stress.Secreted clusterin (sCLU) regulates cell proliferation and chemosensitivity to cisplatin by modulating ERK1/2 signals in human osteosarcoma cells.HCRP1 is downregulated in non-small cell lung cancer and regulates proliferation, invasion, and drug resistance.A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206.Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor.HSPA12B overexpression induces cisplatin resistance in non-small-cell lung cancer by regulating the PI3K/Akt/NF-κB signaling pathway.Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach.
P2860
Q28553961-F840BD04-F2D5-48E4-910B-35C1AC5914BDQ35551953-2AFE0638-712D-4AAE-B2CE-CC9FB74B9F16Q36738620-0BBA3950-66D1-459C-93A0-82E1F845FB4BQ37406949-62DEDF0D-E6D3-481F-A07D-6B2C5A288CA9Q37594244-DFFC01D1-CB81-4EC5-A90B-1CA6BC55ABBCQ38696332-6F6ADF14-B0EA-475D-9429-B7673F07E220Q38721488-BF50DD90-25E5-4388-A0FB-31AF53F16030Q38975225-3F94805A-1197-44A4-85A6-EA0D0B1FEECCQ39039447-4E9F3D3C-3851-4891-AC67-CCB9D1CF4852Q41996659-832200F8-3EE9-4BD3-AEFB-ECC5D1447403Q51395361-1FA797A8-3ACD-45D6-B552-A8E75EE31B27Q52731012-8FD9E7EC-F81C-45FA-8A72-10DF32866341Q53078264-7B484E75-1DDF-4D3C-A72D-2C93C03B0FE6Q53700825-4CDA4A62-CCA4-499E-82A3-970ABB636057Q54259614-AD4B81D2-5AB1-4F0D-9A31-6B9BEE79E184
P2860
Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Activation of ERK1/2 and Akt i ...... ce in human lung cancer cells.
@en
Activation of ERK1/2 and Akt i ...... ce in human lung cancer cells.
@nl
type
label
Activation of ERK1/2 and Akt i ...... ce in human lung cancer cells.
@en
Activation of ERK1/2 and Akt i ...... ce in human lung cancer cells.
@nl
prefLabel
Activation of ERK1/2 and Akt i ...... ce in human lung cancer cells.
@en
Activation of ERK1/2 and Akt i ...... ce in human lung cancer cells.
@nl
P2093
P2860
P1476
Activation of ERK1/2 and Akt i ...... ce in human lung cancer cells.
@en
P2093
Xiang Chun Li
Yi Tang Yao
Zi Min Liu
Zong Xiu Yin
P2860
P304
P356
10.1179/1973947812Y.0000000056
P577
2013-06-01T00:00:00Z